Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - teysuno
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpfb96b1dc5afe6a6be061ee19866b2fbc
identifier: http://ema.europa.eu/identifier
/EU/1/11/669/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Teysuno 15 mg/4.35 mg/11.8 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-fb96b1dc5afe6a6be061ee19866b2fbc
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/11/669/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - teysuno
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Teysuno contains the active substances tegafur gimeracil and oteracil.
Teysuno belongs to the fluoropyrimidine class of medicines known as antineoplastic agents which stop the growth of cancer cells.
Teysuno is prescribed by doctors for:
Do not take Teysuno if you:
Warnings and precautions Talk to your doctor before taking Teysuno if you have:
DPD deficiency: DPD deficiency is a genetic condition that is not usually associated with health problems unless you receive certain medicines. If you have DPD deficiency and take Teysuno, you are at an increased risk of severe side effects (listed under section 4 Possible side effects). It is recommended to test you for DPD deficiency before start of treatment. If you have no activity of the enzyme you should not take Teysuno. If you have a reduced enzyme activity (partial deficiency) your doctor might prescribe a reduced dose. If you have negative test results for DPD deficiency, severe and life-threatening side effects may still occur.
Children and adolescents Teysuno is not recommended for children under 18 years of age.
Other medicines and Teysuno Tell your doctor if you are taking, have recently taken or might take any other medicines.
Also, you need to be particularly careful if you are taking any of the following:
Teysuno with food and drink Teysuno should be taken at least one hour before or one hour after a meal.
Pregnancy and breast-feeding Before starting treatment, you must tell your doctor or pharmacist if you are pregnant, if you think you are pregnant, or if you intend to become pregnant. You must not take Teysuno if you are pregnant or think you might be. Men must use contraceptive measures during and up to 3 months after treatment with Teysuno. Women must use contraceptive measures during and up to 6 months after treatment with Teysuno. If you become pregnant during this time, you must tell your doctor. You must not breastfeed if you are taking Teysuno. Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines Use caution when driving or operating a machine, as Teysuno may make you tired, nauseous or have blurred vision. If you have any doubts talk to your doctor.
Teysuno contains You must not take brivudine (an anti-viral medicine for the treatment of shingles or chickenpox) at the same time as Teysuno treatment (including during any rest periods when you are not taking any Teysuno capsules). If you have taken brivudine you must wait for at least 4 weeks after stopping brivudine before starting to take Teysuno. See also section Do not take Teysuno . Lactose (one type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take Teysuno exactly as your doctor has told you. You should check with your doctor if you are not sure.
Your doctor will tell you what dose you need to take, when to take it and for how long you need to take it. Your dose of Teysuno will be determined by your doctor based on your height and weight. Your doctor may reduce the dose if you have side effects that are too severe.
Teysuno capsules should be swallowed with water at least 1 hour before or 1 hour after a meal. Teysuno must be taken twice daily (morning and evening).
For stomach cancer:
Teysuno capsules are usually taken for 21 days followed by a 7 day rest period (when no capsules are taken). This 28 day period is one treatment cycle. The cycles are repeated.
Teysuno will be given with another anti-cancer medicine called cisplatin. Cisplatin will be stopped after 6 treatment cycles. Teysuno can be continued after stopping cisplatin.
For cancer of the large intestines or rectum that has spread: Teysuno capsules are usually taken for 14 days followed by a 7 day rest period (when no capsules are taken). This 21 day period is one treatment cycle. The cycles are repeated.
Teysuno can be given with other anti-cancer medicines (cisplatin, oxaliplatin, irinotecan or bevacizumab), which will depend on your treatment.
If you take more Teysuno than you should If you take more capsules than you should, contact your doctor immediately.
If you forget to take Teysuno Do not take the missed dose at all and do not take a double dose to make up for a forgotten dose. Instead, continue your regular dosing schedule and check with your doctor.
If you stop taking Teysuno There are no side effects caused by stopping treatment with Teysuno. In case you are using blood thinning or anti-seizure medicines, stopping Teysuno might require that your doctor adjusts the dose of your medicines.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, Teysuno can cause side effects, although not everybody gets them. While some symptoms are easily identified as side effects by the patients themselves, a blood test is required to identify some other symptoms. Your doctor will discuss this with you and will explain the possible risks and benefits of the treatment.
Very common side effects (may affect more than 1 in 10 people) include:
-Diarrhoea, nausea, vomiting, constipation * If you experience diarrhoea more than 4 times a day or in the middle of the night, or if you experience sore mouth accompanied by diarrhoea, stop taking Teysuno and contact your doctor immediately. * If you experience diarrhoea, avoid high-fibre, fatty and spicy foods. * Take plenty of liquids between meals to replace lost fluids and prevent dehydration, low blood volume, and imbalance of salts or chemicals in the blood. * If you experience nausea and vomit a dose of medication, make sure you tell your doctor. Do not replace the dose that has been vomited. * If you vomit more than two times in 24 hours, stop taking Teysuno and contact your doctor immediately. * To help manage nausea and vomiting:
Lie down or take deep breaths when feeling nauseous
Avoid tight clothing
Common side effects (may affect 1 to 10 in 100 people) include:
Uncommon side effects (may affect 1 to 10 in 1,000 people) include:
Rare side effects (may affect 1 to 10 in 10,000 people) and very rare side effects (may affect less than 1 in 10,000 people) include:
If any of the side effects get serious, stop taking Teysuno and tell your doctor immediately. Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton and blister after EXP. The expiry date refers to the last day of the month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Teysuno contains
The active substances are tegafur, gimeracil and oteracil. Each hard capsule contains 15 mg tegafur, 4.35 mg gimeracil, and 11.8 mg oteracil (as monopotassium).
The other ingredients are:
Capsule contents: lactose monohydrate, magnesium stearate Capsule shell: gelatin, red iron oxide (E172), titanium dioxide (E171), sodium lauryl sulphate, talc Ink: red iron oxide (E172), yellow iron oxide (E172), Indigo carmine (E132), carnauba wax, bleached shellac, glyceryl monooleate
What Teysuno looks like and contents of the pack
The hard capsules have a white body and opaque brown cap imprinted "TC448" in grey. They are provided in blisters containing 14 capsules each.
Each pack contains either 42 capsules, 84 capsules or 126 capsules.
Marketing Authorisation Holder Nordic Group B.V. Siriusdreef 2132 WT Hoofddorp The Netherlands
Manufacturer
Nordic Pharma B.V. Siriusdreef 2132 WT Hoofddorp The Netherlands
Millmount Healthcare Limited Block7, City North Business Campus, Stamullen Co. Meath, K32 YDIreland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Nordic Pharma T l/Tel: +32 (0)3 820 5info@nordicpharma.be
Lietuva Nordic Pharma (France) Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com
AMRING FARMA SRL, Tel. : +40 31 620 1RO.OfficeRomania@nordicpharma.com
Luxembourg/Luxemburg Nordic Pharma T l/Tel: +32 (0)3 820 5info@nordicpharma.be esk republika NORDIC Pharma, s.r.o. Tel: +420 241 080 info@nordicpharma.cz Magyarorsz g NORDIC Pharma, s.r.o.
Tel: +420 241 080 info@nordicpharma.cz
Danmark Nordic Drugs Tlf: +46 (0)40 36 66 info@nordicdrugs.dk
Malta Nordic Pharma (France)
Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com
Deutschland Nordic Pharma Tel: +49 (0)89 889 690 info@nordicpharma.de
Nederland Nordic Pharma BV Tel: +31 (0)85 48 35 info-nl@nordicpharma.com
Eesti Nordic Pharma (France) Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com
Norge Nordic Drugs Tlf: +46 40-36 66 info@nordicdrugs.no
Aenorasis S.A. : +30 210 6136info@aenorasis.gr sterreich Nordic Pharma Tel: +49 (0)89 889 690 info@nordicpharma.de Espa a Nordic Pharma (France) Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com Polska AMRING FARMA SRL, Tel. : +40 31 620 1RO.OfficeRomania@nordicpharma.com
France Nordic Pharma (France) Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com
Portugal Nordic Pharma (France)
Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com Hrvatska Nordic Pharma (France) Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com
Ireland Nordic Pharma Ireland Tel: +353 (0)1 400 4info@nordicpharma.ie Rom nia AMRING FARMA SRL, Tel. : +40 31 620 1RO.OfficeRomania@nordicpharma.com
Slovenija NORDIC Pharma, s.r.o. Tel.: +420 241 080 info@nordicpharma.cz sland Vistor hf. S mi: +354 535 7vistor@vistor.is Slovensk republika NORDIC Pharma, s.r.o. Tel.: +420 241 080 info@nordicpharma.cz
Italia Nordic Pharma Tel: +39 (0)2 241 26710/26info@nordicpharma.it
Suomi/Finland Nordic Drugs Puh/Tel: +358 (0)10 231 1info@nordicdrugs.fi
Nordic Pharma (France) Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com Sverige Nordic Drugs AB Tel: +46 (0)40 36 66 info@nordicdrugs.se Latvija Nordic Pharma (France) Tel/ /T l/Tel.: +33 (0)1 70 37 28 info@nordicpharma.com United Kingdom (Northern Ireland) Nordic Pharma Ireland
Tel: +353 (0)1 400 4info@nordicpharma.ie
This leaflet was last revised in Other sources of information Detailed information this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu . Package leaflet: Information for the user
Teysuno 20 mg/5.8 mg/15.8 mg hard capsules tegafur/gimeracil/oteracil
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-fb96b1dc5afe6a6be061ee19866b2fbc
Resource Composition:
Generated Narrative: Composition composition-en-fb96b1dc5afe6a6be061ee19866b2fbc
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/11/669/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - teysuno
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpfb96b1dc5afe6a6be061ee19866b2fbc
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpfb96b1dc5afe6a6be061ee19866b2fbc
identifier:
http://ema.europa.eu/identifier
/EU/1/11/669/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Teysuno 15 mg/4.35 mg/11.8 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en